ArticleProceedings (Baylor University. Medical Center)2025
Refractory cutaneous pseudolymphoma treated with tapinarof.
Article in Proceedings (Baylor University. Medical Center), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous pseudolymphoma (CPL) is a reactive polyclonal T- or B-cell lymphoproliferative process that histopathologically and/or clinically imitates cutaneous lymphoma. We report the case of a 62-year-old woman with a poorly defined, erythematous plaque with papules on the dorsal nose that had been present for years. This lesion was biopsied as an atypical T-cell infiltrate and was clinically diagnosed as a pseudolymphoma. After unsuccessful treatments with mometasone and tacrolimus, the patient was started on tapinarof cream 1%. After 10 months of treatment, there was clinical improvement of the plaque and papules with only slight residual erythema. Further studies and reports will help elucidate the role of tapinarof as a therapeutic option for pseudolymphoma. Based on its safety profile and promising results in other inflammatory and hyperproliferative disorders, it could be considered in refractory cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.